A J Mixson has been working since 1994 in the Pathology Department at the University of Maryland School of Medicine with an initial focus on non-viral delivery of anti-angiogenic “nucleic acids” (plasmids/siRNA/DNAzymes) with liposomes utilizing in vitro or in vivo model systems. Our current research has expanded to developing novel peptides as nucleic acid carriers and as antifungal agents. He has been awarded several US and European patents on gene therapy and anti-angiogenesis. During the last 12 years, our laboratory developed histidine-rich peptides as carriers of nucleic acids. We are particularly interested in the mechanisms that govern the stability and dissociation of histidine-lysine polyplexes. A J Mixson has been working since 1994 in the Pathology Department at the University of Maryland School of Medicine with an initial focus on non-viral delivery of anti-angiogenic “nucleic acids” (plasmids/siRNA/DNAzymes) with liposomes utilizing in vitro or in vivo model systems. Our current research has expanded to developing novel peptides as nucleic acid carriers and as antifungal agents. He has been awarded several US and European patents on gene therapy and anti-angiogenesis. During the last 12 years, our laboratory developed histidine-rich peptides as carriers of nucleic acids. We are particularly interested in the mechanisms that govern the stability and dissociation of histidine-lysine polyplexes.

diagnostics and therapeutics of angiogenesis-related disorders